Show simple item record

dc.contributor.authorArnold, KE
dc.contributor.authorBoxall, ABA
dc.contributor.authorBrown, AR
dc.contributor.authorCuthbert, RJ
dc.contributor.authorGaw, S
dc.contributor.authorHutchinson, TH
dc.contributor.authorJobling, S
dc.contributor.authorMadden, JC
dc.contributor.authorMetcalfe, CD
dc.contributor.authorNaidoo, V
dc.contributor.authorShore, RF
dc.contributor.authorSmits, JE
dc.contributor.authorTaggart, MA
dc.contributor.authorThompson, HM
dc.date.accessioned2017-05-17T08:48:28Z
dc.date.available2017-05-17T08:48:28Z
dc.date.issued2013-08-23
dc.identifier.issn1744-9561
dc.identifier.issn1744-957X
dc.identifier.urihttp://hdl.handle.net/10026.1/9262
dc.description.abstract

<jats:p>The use of human and veterinary pharmaceuticals is increasing. Over the past decade, there has been a proliferation of research into potential environmental impacts of pharmaceuticals in the environment. A Royal Society-supported seminar brought together experts from diverse scientific fields to discuss the risks posed by pharmaceuticals to wildlife. Recent analytical advances have revealed that pharmaceuticals are entering habitats via water, sewage, manure and animal carcases, and dispersing through food chains. Pharmaceuticals are designed to alter physiology at low doses and so can be particularly potent contaminants. The near extinction of Asian vultures following exposure to diclofenac is the key example where exposure to a pharmaceutical caused a population-level impact on non-target wildlife. However, more subtle changes to behaviour and physiology are rarely studied and poorly understood. Grand challenges for the future include developing more realistic exposure assessments for wildlife, assessing the impacts of mixtures of pharmaceuticals in combination with other environmental stressors and estimating the risks from pharmaceutical manufacturing and usage in developing countries. We concluded that an integration of diverse approaches is required to predict ‘unexpected’ risks; specifically, ecologically relevant, often long-term and non-lethal, consequences of pharmaceuticals in the environment for wildlife and ecosystems.</jats:p>

dc.format.extent20130492-20130492
dc.format.mediumElectronic-Print
dc.language.isoen
dc.publisherThe Royal Society
dc.subjectwildlife
dc.subjectendocrine-disrupting chemicals
dc.subjectnon-steroidal anti-inflammatory drugs
dc.subjectvultures
dc.subjectrisk prediction
dc.subjectbioindicators
dc.titleAssessing the exposure risk and impacts of pharmaceuticals in the environment on individuals and ecosystems
dc.typeconference
dc.typeArticle
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/23804293
plymouth.issue4
plymouth.volume9
plymouth.publication-statusPublished
plymouth.journalBiology Letters
dc.identifier.doi10.1098/rsbl.2013.0492
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/BEACh
plymouth.organisational-group/Plymouth/Users by role
dc.publisher.placeEngland
dc.identifier.eissn1744-957X
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1098/rsbl.2013.0492
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeConference Paper/Proceeding/Abstract


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV